Mainz

BERKELEY, Californie et MAINZ, Allemagne et NEW YORK, 19 août 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ : MYNZ) (« Mainz » ou la « Société »), une société de diagnostic en génétique moléculaire spécialisée dans la détection…

BERKELEY, Kalifornien, USA, MAINZ, Deutschland, und NEW YORK, USA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) („Mainz Biomed“ oder das „Unternehmen“), ein Unternehmen im Bereich molekulargenetischer…

BERKELEY, California, MAINZ, Germania e NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'' o “l'Azienda”), un'azienda di diagnostica molecolare genetica specializzata nella diagnosi precoce del cancro,…

BERKELEY, California y MAINZ, Alemania y NUEVA YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'” o la “Compañía”), una firma de diagnóstico de genética molecular que se especializa en la detección temprana…

BERKELEY, Californië en MAINZ, Duitsland en NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ('Mainz' of het 'bedrijf'), een diagnostisch bedrijf op het gebied van moleculaire genetica dat gespecialiseerd is in…

BERKELEY, Calif. and MAINZ, Germany and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'' or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, and …

Renowned Experts to Support ColoAlert’s U.S. Pivotal Clinical Trial and Development of Additional Cancer DiagnosticsDr. Wang is the GI (Gastrointestinal) Division Chief at Columbia University Vagelos College of Physicians and Surgeons and…

Multi-center clinical trial impacting ColoAlert’s profile for FDA submissionOn track to report results by early 2023 BERKELEY, Calif. and MAINZ, Germany, June 28, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed”…

BERKELEY, Calif. and MAINZ, Germany, June 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced…

BERKELEY, Calif. and MAINZ, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced…